Gyre Therapeutics Inc. (GYRE)vsInsmed Inc (INSM)
GYRE
Gyre Therapeutics Inc.
$7.18
+3.46%
HEALTHCARE · Cap: $647.36M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 420% more annual revenue ($606.42M vs $116.59M). GYRE leads profitability with a 4.3% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
GYRE
Hold39
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-735.1%
Fair Value
$0.94
Current Price
$7.18
$6.24 premium
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 33.4% year-over-year
No standout strengths identified
Areas to Watch
1.7% earnings growth
Smaller company, higher risk/reward
4.3% margin — thin
Operating margin of 0.3%
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on Revenue Growth. Revenue growth of 33.4% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : GYRE
The primary concerns for GYRE are EPS Growth, Market Cap, Profit Margin. A P/E of 336.0x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
GYRE profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
GYRE carries more volatility with a beta of 6.92 — expect wider price swings.
GYRE is growing revenue faster at 33.4% — sustainability is the question.
GYRE generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
GYRE scores higher overall (39/100 vs 39/100) and 33.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a biopharmaceutical innovator focused on developing groundbreaking therapies for rare and complex diseases. Leveraging a proprietary platform, the company accelerates the discovery and commercialization of precision treatments tailored to address significant unmet medical needs. With a strong commitment to scientific rigor and patient-centered outcomes, Gyre is strategically positioned to advance its pipeline in gene therapy and precision medicine. Their dedication to research excellence and strategic partnerships highlights their potential for substantial growth in an increasingly competitive biopharmaceutical sector.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?